Related Experiment Video
Updated: Jul 4, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.2K
Cationic solid lipid nanoparticles (SLN) complexed with plasmid DNA enhance prostate cancer cells (PC-3) migration
Fernanda Garcia-Fossa1, Marcelo Bispo de Jesus1
1Nano-cell Interactions Laboratory, Department of Biochemistry & Tissue Biology, Biology Institute, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
Nanotoxicology
|February 1, 2024
Summary
Cationic solid lipid nanoparticles (SLN) unexpectedly enhance prostate cancer cell migration by modulating epithelial-to-mesenchymal transition (EMT) proteins. This finding highlights potential adverse effects of SLN in cancer therapy.
Area of Science:
- Biomedical Nanotechnology
- Cellular Signaling
- Cancer Biology
Background:
- Nanoparticles, particularly cationic solid lipid nanoparticles (SLN), are increasingly used in biomedicine for drug and gene delivery.
- While SLN are recognized for their potential therapeutic benefits and low toxicity, their adverse effects on cellular environments, especially intracellular signaling, are understudied.
- Understanding these molecular impacts is crucial for safe nanomedicine development.
Purpose of the Study:
- To investigate the effects of cationic SLN on intracellular signaling pathways in human prostate cancer cells (PC-3) and non-tumor cells (PNT1A).
- To determine if cationic SLN influence cell migration and the underlying molecular mechanisms.
- To assess the potential therapeutic risks associated with cationic SLN in cancer treatment.
Main Methods:
- Treatment of PNT1A and PC-3 cells with varying concentrations of cationic SLN.
- Analysis of cell migration velocity using microscopy.
- Assessment of protein expression and localization, including vimentin, Smad2, and ZEB1, via Western blotting and immunofluorescence.
Main Results:
- Cationic SLN significantly enhanced the migration of PC-3 prostate cancer cells, but not PNT1A non-tumor cells, in a concentration- and nanoparticle-dependent manner.
- Increased vimentin expression and nuclear translocation of ZEB1 were observed in PC-3 cells treated with cationic SLN, indicating modulation of epithelial-to-mesenchymal transition (EMT).
- Smad2 nuclear translocation was not affected by cationic SLN treatment.
Conclusions:
- Cationic SLN can promote prostate cancer cell motility by upregulating vimentin and facilitating ZEB1 nuclear translocation, key events in EMT.
- The observed effects on cell migration suggest that cationic SLN could potentially exacerbate cancer progression in vivo.
- Further research into the in vitro molecular mechanisms of nanomaterials is essential for ensuring their safe and effective clinical application.
